Global Porcine Vaccine Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Base Year For Estimation | 2024 |
| Market Size (2025) | USD 2.20 Billion |
| Market Size (2030) | USD 3.16 Billion |
| Growth Rate (2025 - 2030) | 7.50% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Global Porcine Vaccine Market Analysis by Mordor Intelligence
The Global Porcine Vaccine Market size is estimated at USD 2.20 billion in 2025, and is expected to reach USD 3.16 billion by 2030, at a CAGR of 7.5% during the forecast period (2025-2030).
The global porcine vaccine market industry is experiencing significant transformation driven by evolving production patterns and technological advancements. Argentina demonstrated remarkable growth with a record-high increase in pork output of 3.9% in 2022, highlighting the expanding production capacity in emerging markets. China continues to dominate global pig farming, maintaining a substantial pig population of 452.56 million in 2022, which underscores the critical importance of effective vaccination programs in large-scale production environments. The industry has witnessed increased focus on sustainable farming practices, with several countries implementing stricter biosecurity measures and health protocols to ensure stable production growth.
Research and development initiatives have gained considerable momentum, with pharmaceutical companies investing heavily in innovative vaccine technologies. The vaccines market witnessed a breakthrough in early 2023 when serYmun Yeast GmbH developed a novel swine vaccine candidate against porcine parvovirus using genetically modified yeast cells. This technological advancement represents a significant shift towards more efficient and safer vaccine production methods. The University of Queensland's successful development of a new vaccine for the Japanese encephalitis virus (JEV) in February 2023 further demonstrates the industry's commitment to addressing emerging health challenges through innovation.
Disease outbreaks continue to shape market dynamics, prompting enhanced focus on preventive measures and vaccine development. In January 2023, South Africa reported a new outbreak of African Swine Fever (ASF) in Gauteng Province, leading to immediate quarantine measures and increased demand for preventive solutions. Vietnam's nationwide distribution of an ASF hog vaccine in February 2023 marked a significant milestone in disease control efforts, representing the first commercial deployment of such a vaccine globally. These developments highlight the industry's rapid response capabilities and the growing importance of vaccination in disease management strategies.
Industry collaboration and technological innovation have become increasingly vital in addressing complex health challenges. Bolivia's pig production reached 117,676 tonnes in 2021, demonstrating the growing importance of emerging markets in global pork production and the subsequent need for advanced porcine vaccine solutions. The industry has witnessed a surge in strategic partnerships between research institutions and commercial entities, focusing on developing next-generation vaccines with improved efficacy and safety profiles. These collaborations have led to significant advancements in vaccine delivery systems and the development of multivalent vaccines that can protect against multiple diseases simultaneously.
Global Porcine Vaccine Market Trends and Insights
Rising Prevalence of Swine Diseases
The increasing burden of various swine diseases continues to be a primary driver for the porcine vaccines market. According to research published in MDPI Viruses in January 2021, Porcine Circovirus (PCV) has resulted in concerning infection rates globally, with seropositivity rates ranging from 20-80% among pig populations and an incidence rate of 60% in affected farms. The severity of PCV infections is further highlighted by the 40% culling rate observed in severely affected pig farms, demonstrating the significant economic impact of these diseases on the swine industry. PCV, being the single-stranded DNA virus with the highest mutation and recombination rate among all ssDNA viruses, poses a persistent threat to pig productivity worldwide.
The emergence and spread of other critical swine diseases have further intensified the need for effective vaccination programs. For instance, in January 2023, the Department of Agriculture, Land Reform, and Rural Development announced a new outbreak of African Swine Fever (ASF) on a farm in Gauteng Province, South Africa, leading to immediate quarantine measures. Similarly, as reported in March 2023, the number of wild boars testing positive for swine fever in South Korea reached 2,890, affecting multiple provinces and highlighting the continuous spread of the disease across regions. These ongoing disease outbreaks and their economic implications have made disease prevention through vaccination an essential aspect of modern pig farming operations.
Technological Advancements in Vaccine Development
The swine vaccines market is experiencing significant growth driven by continuous technological innovations in vaccine development and delivery systems. In the United States, the advancement of vaccine technologies has led to the development of sophisticated solutions, including live vector vaccines, non-replicating recombinant antigen vaccines, nucleic acid-mediated vaccines, and live-gene-deleted vaccines. These technological breakthroughs have enabled the creation of more effective and safer vaccination options for swine disease prevention, contributing to improved animal health outcomes and reduced economic losses in pig farming operations.
The industry has witnessed several breakthrough innovations and product launches that demonstrate the rapid pace of technological advancement. For instance, in March 2022, Boehringer Ingelheim launched the porcine parvovirus vaccine ReproCyc ParvoFLEX, providing safe and efficacious protection for healthy sows and gilts against reproductive failure. Additionally, in December 2022, the company introduced TwistPak, a revolutionary mixing platform that enables swine producers to combine two vaccines - Ingelvac CircoFLEX and Ingelvac MycoFLEX - in a convenient, fast, and flexible way. These innovations in vaccine delivery systems and combination vaccines represent significant technological progress in making vaccination programs more efficient and user-friendly for pig farmers.
Growing Global Pork Production and Consumption
The expansion of global pork production and consumption has emerged as a significant driver for the swine vaccine market. According to recent industry data, Brazil's pork production is projected to reach 5.150 million tons in 2023, representing a 4% increase compared to 2022, with 3.950 million tons destined for the domestic market. This growth in production necessitates robust vaccination programs to maintain healthy pig populations and ensure food safety standards. The increasing scale of pork operations globally has made disease prevention through vaccination a critical component of sustainable pig farming practices.
The rising consumption patterns across various regions have further intensified the need for effective vaccination programs to ensure healthy pig populations. For instance, Agricultural Economic Insights (AEI) reported an upward trend in meat consumption in the United States from 1970 to 2020, with pork being a significant component of this growth. Similarly, in Bolivia, the volume of pig production reached 117,676 tonnes in 2021, marking an 85.6% increase compared to the beginning of the century, according to the country's Ministry of Rural Development and Lands. This substantial growth in production and consumption has made it imperative for producers to implement comprehensive vaccination programs to protect their investments and ensure a consistent supply to meet growing demand.
Segment Analysis: By Target Disease
Swine Influenza Segment in Global Porcine Vaccine Market
The Swine Influenza segment dominates the global porcine vaccine market, commanding approximately 28% market share in 2024. This significant market position is attributed to the high prevalence of swine influenza in pig populations worldwide, with infection rates reaching nearly 100% in exposed pigs. The segment's growth is further supported by continuous product innovations from key market players, such as Boehringer Ingelheim's TwistPak platform launched in 2024, which allows swine producers to combine multiple vaccines efficiently. Additionally, extensive research initiatives and funding support from organizations like the United States Department of Agriculture National Institute of Food and Agriculture (NIFA) have strengthened the segment's position through the development of more effective vaccines against various strains of swine influenza.
Porcine Reproductive and Respiratory Syndrome (PRRS) Segment in Global Porcine Vaccine Market
The PRRS segment is projected to exhibit the fastest growth rate of approximately 8.5% during the forecast period 2024-2029. This accelerated growth is driven by the significant economic impact of PRRS on the global pig industry and the increasing focus on developing advanced vaccination solutions. The segment's expansion is supported by substantial research initiatives and awards for groundbreaking work on practical PRRS control methods, such as those sponsored by Boehringer Ingelheim. Furthermore, the development of innovative vaccine combinations and delivery methods, along with increasing awareness about the economic benefits of PRRS prevention, continues to drive the segment's growth trajectory in the global market.
Remaining Segments in Target Disease Market
The other significant segments in the porcine vaccine market include Porcine Circovirus Associated Disease (PCVAD), Diarrhea, Bordetella Rhinitis, and various other target diseases. The PCVAD segment maintains a strong presence due to its high prevalence and the availability of advanced vaccination solutions. The Diarrhea segment continues to be crucial for neonatal pig health management, with various vaccines targeting different pathogenic causes. The Bordetella Rhinitis segment, while smaller, remains important for respiratory disease prevention in swine populations. Other target diseases collectively represent a significant portion of the market, addressing various emerging and established health challenges in swine populations worldwide.
Segment Analysis: By Technology
Inactivated Vaccines Segment in Global Porcine Vaccine Market
The inactivated vaccines segment continues to dominate the global porcine vaccine market, holding approximately 48% of the market share in 2024. This significant market position is primarily driven by the segment's proven efficacy in preventing diseases such as Porcine Circovirus Type 2 (PCV2), Foot and Mouth Disease, Swine Influenza, and Classical Swine Fever. The widespread adoption of inactivated vaccines can be attributed to their superior safety profile and ability to provide comprehensive protection against multiple strains of viruses. The segment's growth is further supported by increasing research activities focused on developing advanced inactivated vaccine formulations, particularly in response to emerging swine diseases and variants. Major pharmaceutical companies are actively expanding their inactivated vaccine portfolios, with several new product launches and approvals strengthening the segment's market position.
Recombinant Vaccines Segment in Global Porcine Vaccine Market
The recombinant vaccines segment is projected to experience the fastest growth in the global porcine vaccine market, with an expected growth rate of approximately 8% during the forecast period 2024-2029. This accelerated growth is driven by technological advancements in genetic engineering and increasing preference for more targeted and efficient vaccination solutions. Recombinant vaccines offer several advantages over traditional vaccines, including improved safety profiles, greater efficacy, and the ability to target specific antigens. The segment is witnessing substantial investments in research and development, particularly in developing vaccines against complex diseases like Classical Swine Fever Virus (CSFV). The adoption of recombinant vaccines is also being fueled by their ability to overcome trade barriers associated with conventional vaccines and their potential to provide broader protection against multiple strains of viruses.
Remaining Segments in Porcine Vaccine Market by Technology
The other significant segments in the porcine vaccine market include live attenuated vaccine for pig market, toxoid vaccines, and other emerging technologies. Live-attenuated vaccines continue to be a crucial segment, offering strong immune responses and long-lasting protection against various swine diseases. Toxoid vaccines play a vital role in preventing specific bacterial diseases in swine populations, particularly in intensive farming operations. The 'Others' category encompasses emerging vaccine technologies and experimental approaches that show promise for future applications. Each of these segments contributes uniquely to the market's diversity, offering veterinarians and farmers a comprehensive range of options for swine disease prevention and control, while continuing to evolve with technological advancements and changing industry needs.
Segment Analysis: By Route of Administration
Injectable Segment in Global Porcine Vaccine Market
The injectable segment dominates the global porcine vaccine market, accounting for approximately 73% of the total market share in 2024. This significant market position is attributed to several key factors, including the high efficacy and precise dosing capabilities of injectable vaccines. Injectable vaccines are delivered directly into the pig's muscle tissue, enabling quick absorption into the bloodstream and transportation throughout the body, resulting in a rapid and effective immune response against target pathogens. The segment's dominance is further strengthened by the reduced risk of vaccine interference and the availability of various combination vaccines that can be administered through a single injection. Major pharmaceutical companies continue to focus on developing advanced injectable formulations, with innovations in delivery mechanisms and combination vaccines driving the segment's growth. The preference for injectable vaccines among veterinarians and pig farmers remains strong due to their reliable performance and established track record in disease prevention.
Oral Segment in Global Porcine Vaccine Market
The oral segment is emerging as the fastest-growing route of administration in the porcine vaccine market, projected to grow at approximately 8% from 2024 to 2029. This growth trajectory is driven by the increasing demand for mass vaccination solutions that can be administered through feed or drinking water, offering significant advantages in terms of labor efficiency and reduced animal stress. The segment is witnessing substantial innovation in vaccine formulation technologies that enhance stability and bioavailability when administered orally. Pharmaceutical companies are investing in research and development to overcome traditional challenges associated with oral vaccines, such as degradation in the digestive tract and ensuring uniform dosage across herds. The convenience of oral administration, particularly in large-scale farming operations, is becoming increasingly attractive to pig producers. Additionally, the development of novel oral vaccine delivery systems and improved adjuvants is expected to further boost the adoption of oral vaccines in the coming years.
Global Porcine Vaccine Market Geography Segment Analysis
Porcine Vaccine Market in North America
The North American porcine vaccine market demonstrates robust growth driven by advanced healthcare infrastructure, increasing research and development activities, and stringent regulations for animal health. The United States leads the regional market with extensive pig farming operations and well-established vaccination protocols, followed by Canada and Mexico. The region benefits from the presence of major pharmaceutical companies and research institutions actively involved in developing innovative swine vaccine solutions. Government initiatives supporting animal health and disease prevention further strengthen the market dynamics across these countries.
Porcine Vaccine Market in United States
The United States dominates the North American porcine vaccine market, holding approximately 75% of the regional market share. The country's market leadership is attributed to its highly organized farming structures, advanced vaccine development capabilities, and strong regulatory framework. The presence of leading pharmaceutical companies and research institutions contributes significantly to market growth. The country's focus on technological advancements in vaccine development, including live vector vaccines, non-replicating recombinant antigen vaccines, and nucleic acid-mediated vaccines, demonstrates its commitment to innovation in this sector.
Porcine Vaccine Market in Canada
Canada emerges as the fastest-growing market in North America, with an expected growth rate of approximately 7% from 2024 to 2029. The country's growth is driven by increasing investments in research and development, particularly in vaccine development infrastructure. The Canadian government's proactive approach to disease prevention and control, coupled with rising awareness about animal health, supports market expansion. The country's strategic focus on biosecurity measures and emergency preparedness further enhances its market potential.
Porcine Vaccine Market in Europe
The European porcine vaccine market exhibits strong growth potential supported by advanced veterinary healthcare infrastructure and an increasing focus on animal welfare. The region benefits from well-established regulatory frameworks and significant investments in research and development. Germany and Spain lead the market with extensive pig farming operations, while France demonstrates remarkable growth potential. The presence of major vaccine manufacturers and research institutions across these countries further strengthens the regional market dynamics.
Porcine Vaccine Market in Germany
Germany maintains its position as the largest market in Europe, commanding approximately 20% of the regional market share. The country's leadership is attributed to its advanced technological capabilities, strong research infrastructure, and well-established pig farming industry. German market growth is supported by continuous innovation in vaccine development, strategic initiatives by key market players, and robust distribution networks. The country's emphasis on preventive healthcare measures and animal welfare standards further reinforces its market dominance.
Porcine Vaccine Market in France
France demonstrates the highest growth potential in Europe, with an anticipated growth rate of approximately 9% from 2024 to 2029. The country's impressive growth is driven by increasing research activities, rising awareness about animal health, and strong government support for the livestock sector. France's strategic position in pork production and export, coupled with its focus on innovative vaccine solutions, contributes to its rapid market expansion. The country's commitment to disease prevention and control measures further accelerates market growth.
Porcine Vaccine Market in Asia-Pacific
The Asia-Pacific region represents a significant market for porcine vaccines, characterized by large-scale pig farming operations and an increasing focus on animal health. The region encompasses diverse markets including China, Japan, India, Australia, and South Korea, each contributing uniquely to the overall market landscape. Rising awareness about animal healthcare, growing investments in veterinary infrastructure, and increasing demand for pork products drive market growth across these countries.
Porcine Vaccine Market in China
China emerges as the dominant force in the Asia-Pacific porcine vaccine market, driven by its massive pig farming industry and comprehensive vaccination programs. The country's market leadership is supported by substantial investments in research and development, growing awareness about animal health, and strong government support for the livestock sector. China's focus on developing advanced vaccine solutions and improving distribution networks further strengthens its market position.
Porcine Vaccine Market in South Korea
South Korea demonstrates remarkable growth potential in the Asia-Pacific region, driven by its advanced technological capabilities and strong focus on animal health. The country's market expansion is supported by increasing research and development activities, rising awareness about disease prevention, and growing investments in veterinary infrastructure. South Korea's commitment to innovative hog vaccine solutions and stringent quality standards contributes to its rapid market growth.
Porcine Vaccine Market in Middle East & Africa
The Middle East & Africa porcine vaccine market shows steady development, primarily driven by specific regions where pig farming is permitted. The market encompasses diverse territories including GCC countries and South Africa, with varying levels of market penetration and growth potential. South Africa emerges as both the largest and fastest-growing market in the region, supported by its well-established pig farming industry and increasing focus on animal health measures. The region's market dynamics are influenced by regulatory frameworks, cultural factors, and growing awareness about animal healthcare in specific territories.
Porcine Vaccine Market in South America
The South American porcine vaccine market demonstrates significant growth potential, supported by extensive pig farming operations and an increasing focus on animal health. The region, primarily led by Brazil and Argentina, shows strong market development driven by rising awareness about disease prevention and control. Brazil emerges as both the largest and fastest-growing market in the region, supported by its substantial pig farming industry and increasing investments in vaccine research and development. The region's market expansion is further strengthened by growing export opportunities and improving veterinary healthcare infrastructure.
Competitive Landscape
Top Companies in Global Porcine Vaccine Market
The porcine vaccine market is characterized by continuous product innovation focused on developing more effective vaccines against emerging disease strains and variants. Companies are investing heavily in research and development to create advanced vaccine formulations, particularly for diseases like African Swine Fever and Porcine Reproductive and Respiratory Syndrome. Operational agility is demonstrated through flexible manufacturing capabilities and robust distribution networks, allowing quick responses to disease outbreaks and market demands. Strategic partnerships with research institutions and veterinary organizations have become increasingly common to enhance product development and market reach. Geographic expansion, particularly in Asia-Pacific markets where pig farming is extensive, remains a key growth strategy, with companies establishing local manufacturing facilities and strengthening their distribution channels.
Consolidated Market with Strong Regional Players
The global porcine vaccines market exhibits a moderately consolidated structure, with a mix of large multinational pharmaceutical companies and specialized animal health firms competing for market share. Major pharmaceutical conglomerates leverage their extensive research capabilities and global distribution networks to maintain market leadership, while regional specialists capitalize on their deep understanding of local markets and strong relationships with pig farmers. The market demonstrates varying levels of consolidation across regions, with developed markets showing higher consolidation compared to emerging markets where local players maintain a significant presence.
Merger and acquisition activities in the porcine vaccine market sector have been primarily driven by the need to expand product portfolios and strengthen geographic presence. Companies are increasingly pursuing strategic acquisitions to gain access to new technologies, enhance their research capabilities, and expand their market reach in high-growth regions. Vertical integration strategies are also becoming more prevalent, with companies acquiring or partnering with distribution networks to improve market access and customer service capabilities.
Innovation and Market Access Drive Success
Success in the porcine medicine vaccines market increasingly depends on companies' ability to develop innovative solutions addressing emerging disease challenges while maintaining cost-effectiveness. Market leaders are focusing on developing combination vaccines that provide protection against multiple diseases, thereby offering greater value to pig farmers. Building strong relationships with key stakeholders, including veterinary professionals, research institutions, and regulatory bodies, has become crucial for maintaining market position and ensuring product adoption. Companies are also investing in digital technologies and data analytics to better understand disease patterns and optimize vaccine development.
For new entrants and smaller players, success lies in identifying and serving underserved market segments and developing specialized products for specific regional needs. Building robust distribution networks and establishing strong technical support services are essential for gaining market share. The increasing focus on biosecurity and disease prevention in pig farming presents opportunities for companies to differentiate themselves through comprehensive health management solutions. Regulatory compliance and quality assurance remain critical success factors, particularly as governments worldwide strengthen their oversight of animal health products.
Global Porcine Vaccine Industry Leaders
-
Zoetis Inc.
-
Hipra
-
Elanco
-
Boehringer Ingelheim
-
Vetoquinol
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- In June 2022, Merck Animal Health received license approval in the United States from the Department of Agriculture (USDA) for its Circumvent CML vaccine. Merck issued a press release that claims Circumvent CML is the first-ready-to-use, single-dose vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d.
- In April 2022, Scientists with the United States Department of Agriculture's Agricultural Research Service (ARS) announced that a vaccine candidate for African Swine Fever (ASF) passed an important safety test required for regulatory approval, moving the vaccine one step closer to commercial availability.
Global Porcine Vaccine Market Report Scope
Porcine Vaccines are a clinical and administrative drug that ameliorates swine health by protecting them from various bacteria, viruses, and other pathogens. The market is segmented by Target Disease (Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCVAD), Other Target Diseases), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| Diarrhea |
| Swine Influenza |
| Arthritis |
| Bordetella Rhinitis |
| Porcine Reproductive and Respiratory Syndrome (PRRS) |
| Porcine Circovirus Associated Disease (PCVAD) |
| Other Target Diseases |
| Inactivated Vaccines |
| Live Attenuated Vaccines |
| Toxoid Vaccines |
| Recombinant Vaccines |
| Others |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle-East and Africa | GCC |
| South Africa | |
| Rest of Middle-East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Target Disease | Diarrhea | |
| Swine Influenza | ||
| Arthritis | ||
| Bordetella Rhinitis | ||
| Porcine Reproductive and Respiratory Syndrome (PRRS) | ||
| Porcine Circovirus Associated Disease (PCVAD) | ||
| Other Target Diseases | ||
| By Technology | Inactivated Vaccines | |
| Live Attenuated Vaccines | ||
| Toxoid Vaccines | ||
| Recombinant Vaccines | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Middle-East and Africa | GCC | |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
How big is the Global Porcine Vaccine Market?
The Global Porcine Vaccine Market size is expected to reach USD 2.20 billion in 2025 and grow at a CAGR of 7.5% to reach USD 3.16 billion by 2030.
What is the current Global Porcine Vaccine Market size?
In 2025, the Global Porcine Vaccine Market size is expected to reach USD 2.20 billion.
Who are the key players in Global Porcine Vaccine Market?
Zoetis Inc., Hipra, Elanco, Boehringer Ingelheim and Vetoquinol are the major companies operating in the Global Porcine Vaccine Market.
Which is the fastest growing region in Global Porcine Vaccine Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Porcine Vaccine Market?
In 2025, the North America accounts for the largest market share in Global Porcine Vaccine Market.
What years does this Global Porcine Vaccine Market cover, and what was the market size in 2024?
In 2024, the Global Porcine Vaccine Market size was estimated at USD 2.04 billion. The report covers the Global Porcine Vaccine Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Porcine Vaccine Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Page last updated on:
